- Home
- INTS vs MULN Comparison
INTS vs MULN Comparison
Compare INTS & MULN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INTS
- MULN
- Stock Information
- Founded
- INTS 2012
- MULN 2014
- Country
- INTS United States
- MULN United States
- Employees
- INTS N/A
- MULN N/A
- Industry
- INTS Biotechnology: Pharmaceutical Preparations
- MULN Auto Manufacturing
- Sector
- INTS Health Care
- MULN Consumer Discretionary
- Exchange
- INTS Nasdaq
- MULN Nasdaq
- Market Cap
- INTS 8.0M
- MULN 6.5M
- IPO Year
- INTS 2023
- MULN N/A
- Fundamental
- Price
- INTS $0.31
- MULN $0.17
- Analyst Decision
- INTS Strong Buy
- MULN
- Analyst Count
- INTS 3
- MULN 0
- Target Price
- INTS $8.50
- MULN N/A
- AVG Volume (30 Days)
- INTS 3.1M
- MULN 31.3M
- Earning Date
- INTS 08-07-2025
- MULN 08-11-2025
- Dividend Yield
- INTS N/A
- MULN N/A
- EPS Growth
- INTS N/A
- MULN N/A
- EPS
- INTS N/A
- MULN N/A
- Revenue
- INTS N/A
- MULN $8,931,612.00
- Revenue This Year
- INTS N/A
- MULN N/A
- Revenue Next Year
- INTS N/A
- MULN N/A
- P/E Ratio
- INTS N/A
- MULN N/A
- Revenue Growth
- INTS N/A
- MULN 2136.62
- 52 Week Low
- INTS $0.26
- MULN $0.16
- 52 Week High
- INTS $5.10
- MULN $141,600,000.00
- Technical
- Relative Strength Index (RSI)
- INTS 40.08
- MULN 21.58
- Support Level
- INTS $0.26
- MULN $1.62
- Resistance Level
- INTS $0.32
- MULN $0.35
- Average True Range (ATR)
- INTS 0.04
- MULN 0.19
- MACD
- INTS 0.02
- MULN 71.04
- Stochastic Oscillator
- INTS 49.20
- MULN 0.74
About INTS Intensity Therapeutics Inc. Common stock
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.
About MULN Mullen Automotive Inc.
Mullen Automotive Inc is engaged in manufacturing electric vehicles and building energy solutions. Its portfolio of vehicles is predominantly comprised of commercial trucks and other electric vehicles and includes; Mullen Class 1 Cargo Van, Mullen Three, Bollinger B4 Chassis Cab, and Mullen I-GO. The company's operating segments are Bollinger which derives maximum revenue, and Mullen Commercial.